Skip to main content

Bridion Side Effects

Generic name: sugammadex

Medically reviewed by Last updated on Nov 11, 2023.

Note: This document contains side effect information about sugammadex. Some dosage forms listed on this page may not apply to the brand name Bridion.

Applies to sugammadex: intravenous solution.

Serious side effects of Bridion

Along with its needed effects, sugammadex (the active ingredient contained in Bridion) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking sugammadex:

More common

Less common

Incidence not known

Other side effects of Bridion

Some side effects of sugammadex may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to sugammadex: intravenous solution.


The most commonly reported adverse reactions have included vomiting, pain, nausea, hypotension and headache.[Ref]


Cases of marked bradycardia, some resulting in cardiac arrest, have occurred within minutes of administering this drug. Cardiac electrophysiology studies have shown that at 2 times the maximum recommended dose, the QT interval was not prolonged to any clinically relevant extent.[Ref]

Common (1% to 10%): Abnormal ECG, hypertension, hypotension, tachycardia, bradycardia, abnormal or prolonged QT interval

Postmarketing reports: Bradycardia with cardiac arrest, atrial fibrillation, atrioventricular block, cardiac/cardiorespiratory arrest, ST segment changes, supraventricular tachycardia/extrasystoles, tachycardia, ventricular fibrillation, and ventricular tachycardia[Ref]


Uncommon (0.1% to 1%): Anaphylaxis, hypersensitivity reactions

Postmarketing reports: Anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, Type I hypersensitivity[Ref]

In a dedicated hypersensitivity study in healthy volunteers, anaphylaxis occurred in 1 of 299 patients (0.3%). This patient experienced anaphylaxis with the first dose (16 mg/kg) and symptoms included conjunctival edema, urticaria, erythema, swelling of the uvula, and reduction in peak expiratory flow. Hypersensitivity reactions including nausea, pruritus, and urticaria occurred in a dose-related manner with more reactions occurring in the 16 mg/kg dose group compared to the 4 mg/kg group.

Anaphylaxis has been reported at all doses. The most commonly described reactions included in reports of anaphylaxis have included dermatologic reactions (e.g., urticaria, rash, erythema, flushing, and skin eruption), and clinically important hypotension often requiring vasopressors for circulatory support. There have also been reports of prolonged hospitalization with the use of additional respiratory support in some patients.[Ref]


Common (1% to 10%): Nausea (up to 26%), vomiting (up to 15%)

Uncommon (0.1% to 1%): Abdominal pain, flatulence, dry mouth[Ref]


Bronchospasm was observed in patients with a history of pulmonary complications.[Ref]

Common (1% to 10%): Airway complication of anesthesia, oropharyngeal pain, cough

Frequency not reported: Bronchospasm

Postmarketing reports: Laryngospasm, dyspnea, wheezing, pulmonary edema, respiratory arrest[Ref]


Common (1% to 10%): Pruritus, erythema[Ref]


Common (1% to 10%): Decreased red blood cell count, hematoma, anemia[Ref]


Common (1% to 10%): Injection site pain[Ref]


Common (1% to 10%): Hypocalcemia[Ref]


Common (1% to 10%): Extremity pain, musculoskeletal pain, myalgia, creatine phosphokinase increased[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, hypoesthesia, dysgeusia[Ref]


Very common (10% or more): Pain (up to 52%)

Common (1% to 10%): Procedural complication, anesthetic complication, wound hemorrhage, pyrexia, chills, ear and labyrinth disorders

Uncommon (0.1% to 1%): Recurrence of neuromuscular blockade[Ref]

In clinical studies using this drug at doses labeled for the depth of neuromuscular blockade (n=2022), less than 1% of patients were observed to have recurrence of neuromuscular blockade as based on neuromuscular monitoring or clinical evidence.

Airway complications of anesthesia have included bucking against the endotracheal tube, coughing, mild bucking, arousal reaction during surgery, coughing during the anesthetic procedure or during surgery, or anesthetic procedure related spontaneous breath of patient. Anesthetic complications include reports of the restoration of neuromuscular function (e.g., movement of limb or body, grimacing, or suckling on the endotracheal tube). Procedural complications include coughing, tachycardia, bradycardia, movement, and increased heart rate.[Ref]


Common (1% to 10%): Insomnia, anxiety, restlessness, depression, sleep disorder[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. Cerner Multum, Inc. "Australian Product Information."

3. (2015) "Product Information. Bridion (sugammadex)." Merck & Co., Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.